Риск развития сердечно-сосудистых осложнений при употреблении стимуляторов физической работоспособности

В настоящее время увеличивается число лиц, привлеченных к регулярным занятиям физической культурой и спортом. Зачастую данное явление сопровождается приемом спортивных пищевых биологически активных добавок – БАДов, а также стимуляторов физической работоспособности. Приводятся данные о частоте приема стимуляторов физической работоспособности среди профессиональных спортсменов, а также данные об использовании наиболее популярных спортивных пищевых добавок у лиц молодого возраста. Особое внимание уделяется влиянию подобных средств на сердечно-сосудистую систему спортсменов. Описываются негативные кардиальные эффекты допинговых средств, а также приводятся описания клинических случаев смерти спортсменов в результате употребления подобных средств.

1. Grivetti LE, Applegate EA. From Olympia to Atlanta: A Cultural-Historical Perspective on Diet and Athletic Training. The Journal of Nutrition. 1997;127(5):860S-868S. DOI: 10.1093/jn/127.5.860S

2. ВАДА. Всемирный антидопинговый кодекс. Версия 3.0. 20 февраля 2003 г. Доступно на: https://www.wada-ama.org/sites/default/files/resources/files/wada_code_2003_en.pdf]

3. Overbye M, Wagner U. Between medical treatment and performance enhancement: An investigation of how elite athletes experience Therapeutic Use Exemptions. International Journal of Drug Policy. 2013;24(6):579–88. DOI: 10.1016/j.drugpo.2013.03.007

4. Mazzeo F, Monda V, Santamaria S, Nigro E, Valenzano A, Villano I et al. Antidoping program: an important factor in the promotion and protection of the integrity of sport and athlete’s health. The Journal of Sports Medicine and Physical Fitness. 2018;58(7–8):1135–45. DOI: 10.23736/S0022-4707.17.07722-2

5. Morente-Sánchez J, Zabala M. Doping in Sport: A Review of Elite Athletes’ Attitudes, Beliefs, and Knowledge. Sports Medicine. 2013;43(6):395–411. DOI: 10.1007/s40279-013-0037-x

6. Angell PJ, Chester N, Sculthorpe N, Whyte G, George K, Somauroo J. Performance enhancing drug abuse and cardiovascular risk in athletes: implications for the clinician. British Journal of Sports Medicine. 2012;46(Suppl 1):i78–84. DOI: 10.1136/bjsports-2012-091186

7. La Gerche A, Brosnan MJ. Cardiovascular Effects of Performance-Enhancing Drugs. Circulation. 2017;135(1):89–99. DOI: 10.1161/CIRCULATIONAHA.116.022535

8. Goldman A, Basaria S. Adverse health effects of androgen use. Molecular and Cellular Endocrinology. 2018;464:46–55. DOI: 10.1016/j.mce.2017.06.009

9. Connor JM, Mazanov J. Would you dope? A general population test of the Goldman dilemma. British Journal of Sports Medicine. 2009;43(11):871–2. DOI: 10.1136/bjsm.2009.057596

10. American Dietetic Association, Dietitians of Canada, American College of Sports Medicine, Rodriguez NR, Di Marco NM, Langley S. American College of Sports Medicine position stand. Nutrition and Athletic Performance. Medicine & Science in Sports & Exercise. 2009;41(3):709–31. DOI: 10.1249/MSS.0b013e31890eb86

11. Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal Relation between Endogenous Testosterone and Cardiovascular Disease Risk Factors in Middle-aged Men: A 13-Year Follow-up of Former Multiple Risk Factor Intervention Trial Participants. American Journal of Epidemiology. 1997;146(8):609–17. DOI: 10.1093/oxfordjournals.aje.a009326

12. Bueno A, Carvalho FB, Gutierres JM, Lhamas C, Andrade CM. A comparative study of the effect of the dose and exposure duration of anabolic androgenic steroids on behavior, cholinergic regulation, and oxidative stress in rats. PLOS ONE. 2017;12(6):e0177623. DOI: 10.1371/journal.pone.0177623

13. Momaya A, Fawal M, Estes R. Performance-Enhancing Substances in Sports: A Review of the Literature. Sports Medicine. 2015;45(4):517–31. DOI: 10.1007/s40279-015-0308-9

14. Kinahan A, Budgett R, Mazzoni I. Structure and Development of the List of Prohibited Substances and Methods. Medicine and Sport Science. 2017;62:39–54. DOI: 10.1159/000460699

15. Ljungqvist A. Brief History of Anti-Doping. Medicine and Sport Science. 2017;62:1–10. DOI: 10.1159/000460680

16. Turillazzi E, Perilli G, Di Paolo M, Neri M, Riezzo I, Fineschi V. Side Effects of AAS Abuse: An Overview. Mini-Reviews in Medicinal Chemistry. 2011;11(5):374–89. DOI: 10.2174/138955711795445925

17. Di Paolo M, Agozzino M, Toni C, Luciani AB, Molendini L, Scaglione M et al. Sudden anabolic steroid abuse-related death in athletes. International Journal of Cardiology. 2007;114(1):114–7. DOI: 10.1016/j.ijcard.2005.11.033

18. Baggish AL, Weiner RB, Kanayama G, Hudson JI, Lu MT, Hoffmann U et al. Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use. Circulation. 2017;135(21):1991–2002. DOI: 10.1161/CIRCULATIONAHA.116.026945

19. Donike M, Zimmermann J, Bärwald KR, Schänzer W, Christ V, Klostermann K et al. Routinebestimmung von Anabolika im Harn. Deutsche Zeitschrift für Sportmedizin. 1984;35(1):14–24. [Av. at: https://www.bisp-surf.de/Record/PU198402020459/HierarchyTree?recordID=PU198402020459#solr]

20. Donike M, Geyer H, Gotzmann A, Mareck-Engelke U, Rauth S. Evaluation of Longitudinal Studies, the Determination of Subject Based Reference Ranges of the Testosterone/Epitestosterone Ratio. P. 33–39. In: Donike M, Rauth S, Mareck-Engelke U, Geyer H, Nitschke R. Recent advances in doping analysis. - Koln: Sport und Buch Straub;1994. [Av. at: https://www.dshs-koeln.de/fileadmin/redaktion/Institute/Biochemie/PDF/Literatur_ID825.pdf]

21. Schänzer W, Geyer H, Gotzmann A, Mareck-Engelke U. Geyer H, Mareck-Engelke U, Schänzer W, Donike M. The Cologne protocol to follow up high testosterone/epitestosterone ratios. In: Recent advances in doping analysis-Koln: Sport und Buch Straub;1997. [Av. at: https://www.dshs-koeln.de/fileadmin/redaktion/Institute/Biochemie/PDF/Literatur_ID362.pdf]

22. Luke JL, Farb A, Virmani R, Sample RH. Sudden cardiac death during exercise in a weight lifter using anabolic androgenic steroids: pathological and toxicological findings. Journal of Forensic Sciences. 1990;35(6):1441–7. PMID: 2148179

23. Dickerman RD, Schaller F, Prather I, McConathy WJ. Sudden Cardiac Death in a 20-Year-Old Bodybuilder Using Anabolic Steroids. Cardiology. 1995;86(2):172–3. DOI: 10.1159/000176867

24. Dickerman RD, Mcconathy WJ, Schaller F, Zachariah NY. Cardiovascular complications and anabolic steroids. European Heart Journal. 1996;17(12):1912–1912. DOI: 10.1093/oxfordjournals.eurheartj.a014812

25. Lindqvist Bagge AS, Rosén T, Fahlke C, Ehrnborg C, Eriksson BO, Moberg T et al. Somatic effects of AAS abuse: A 30-years follow-up study of male former power sports athletes. Journal of Science and Medicine in Sport. 2017;20(9):814–8. DOI: 10.1016/j.jsams.2017.03.008

26. Karila TA, Karjalainen JE, Mäntysaari MJ, Viitasalo MT, Seppälä TA. Anabolic Androgenic Steroids Produce Dose-Dependent Increase in Left Ventricular Mass in Power Athletes, and this Effect is Potentiated by Concomitant Use of Growth Hormone. International Journal of Sports Medicine. 2003;24(5):337–43. DOI: 10.1055/s-2003-40702

27. Zgliczynski S, Ossowski M, Slowinska-Srzednicka J, Brzezinska A, Zgliczynski W, Soszynski P et al. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis. 1996;121(1):35–43. DOI: 10.1016/0021-9150(95)05673-4

28. Donike M, Ueki M, Kuroda Y, Geyer H, Nolteernsting E, Rauth S et al. Detection of dihydrotestosterone (DHT) doping: alterations in the steroid profile and reference ranges for DHT and its 5 alphametabolites. The Journal of Sports Medicine and Physical Fitness. 1995;35(4):235–50. PMID: 8776070

29. Sottas P-E, Baume N, Saudan C, Schweizer C, Kamber M, Saugy M. Bayesian detection of abnormal values in longitudinal biomarkers with an application to T/E ratio. Biostatistics. 2007;8(2):285–96. DOI: 10.1093/biostatistics/kxl009

30. Mareck U, Geyer H, Opfermann G, Thevis M, Schänzer W. Factors influencing the steroid profile in doping control analysis. Journal of Mass Spectrometry. 2008;43(7):877–91. DOI: 10.1002/jms.1457

31. Kennedy MC, Lawrence C. Anabolic steroid abuse and cardiac death. The Medical Journal of Australia. 1993;158(5):346–8. PMID: 8474379

32. Piper T, Emery C, Saugy M. Recent developments in the use of isotope ratio mass spectrometry in sports drug testing. Analytical and Bioanalytical Chemistry. 2011;401(2):433–47. DOI: 10.1007/s00216-011-4886-6

33. Becchi M, Aguilera R, Farizon Y, Flament M-M, Casabianca H, James P. Gas chromatography/combustion/isotope-ratio mass spectrometry analysis of urinary steroids to detect misuse of testosterone in sport. Rapid Communications in Mass Spectrometry. 1994;8(4):304–8. DOI: 10.1002/rcm.1290080404

34. Dalton JT, Mukherjee A, Zhu Z, Kirkovsky L, Miller DD. Discovery of Nonsteroidal Androgens. Biochemical and Biophysical Research Communications. 1998;244(1):1–4. DOI: 10.1006/bbrc.1998.8209

35. Van Renterghem P, Van Eenoo P, Van Thuyne W, Geyer H, Schänzer W, Delbeke FT. Validation of an extended method for the detection of the misuse of endogenous steroids in sports, including new hydroxylated metabolites. Journal of Chromatography B. 2008;876(2):225–35. DOI: 10.1016/j.jchromb.2008.10.047

36. Van Renterghem P, Van Eenoo P, Geyer H, Schänzer W, Delbeke FT. Reference ranges for urinary concentrations and ratios of endogenous steroids, which can be used as markers for steroid misuse, in a Caucasian population of athletes. Steroids. 2010;75(2):154–63. DOI: 10.1016/j.steroids.2009.11.008

37. Martínez-Quintana E, Sáiz-Udaeta B, Marrero-Negrín N, López-Mérida X, Rodríguez-González F, Nieto-Lago V. Androgenic Anabolic Steroid, Cocaine and Amphetamine Abuse and Adverse Cardiovascular Effects. International Journal of Endocrinology and Metabolism. 2013;11(4):e8755. DOI: 10.5812/ijem.8755

38. Мелехов А.В., Рязанцева Е.Е., Гендлин Г.Е., Сторожаков Г.И., Сертакова О.В., Родоман Г.В. Кардиомиопатия вследствие длительного приема анаболических стероидов. Атмосфера. Новости кардиологии. 2013;2:24-8

39. Geyer H, Braun H, Burke LM, Stear SJ, Castell LM. A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance: Part 22. British Journal of Sports Medicine. 2011;45(9):752–4. DOI: 10.1136/bjsports-2011-090180

40. Vernec A, Stear SJ, Burke LM, Castell LM. A–Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance: Part 48. British Journal of Sports Medicine. 2013;47(15):998–1000. DOI: 10.1136/bjsports-2013-092941

41. Guddat S, Fußhöller G, Geyer H, Thomas A, Braun H, Haenelt N et al. Clenbuterol - regional food contamination a possible source for inadvertent doping in sports. Drug Testing and Analysis. 2012;4(6):534–8. DOI: 10.1002/dta.1330

42. Thevis M, Geyer L, Geyer H, Guddat S, Dvorak J, Butch A et al. Adverse analytical findings with clenbuterol among U-17 soccer players attributed to food contamination issues. Drug Testing and Analysis. 2013;5(5):372–6. DOI: 10.1002/dta.1471

43. Nicoli R, Petrou M, Badoud F, Dvorak J, Saugy M, Baume N. Quantification of clenbuterol at trace level in human urine by ultra-high pressure liquid chromatography–tandem mass spectrometry. Journal of Chromatography A. 2013;1292:142–50. DOI: 10.1016/j.chroma.2012.12.008

44. Isenmann E, Ambrosio G, Joseph JF, Mazzarino M, de la Torre X, Zimmer P et al. Ecdysteroids as non-conventional anabolic agent: performance enhancement by ecdysterone supplementation in humans. Archives of Toxicology. 2019;93(7):1807–16. DOI: 10.1007/s00204-019-02490-x

45. Anderson LJ, Tamayose JM, Garcia JM. Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects. Molecular and Cellular Endocrinology. 2018;464:65–74. DOI: 10.1016/j.mce.2017.06.010

46. Бакшеев В.И., Коломоец Н.М. Эритропоэтин в клинической практике. Клиническая медицина. 2007;85(9):30-7

47. Qunini WY, Henrich WL. Hypertension following erythropoiesisstimulating agents (ESAs) in chronic kidney disease. UpToDate. Internet. [Av. at: https://www.uptodate.com/contents/hypertensionfollowing-erythropoiesis-stimulating-agents-esas-in-chronic-kidneydisease?search=Hypertension%20following%20erythropoietin%20in%20chronic%20kidney%20disease&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1]

48. Kanbay M, Akcay A, Delibasi T, Uz B, Kaya A, Koca C et al. Comparison of effects of darbepoetin alfa and epoetin alfa on serum endothelin level and blood pressure. Advances in Therapy. 2007;24(2):346–52. DOI: 10.1007/BF02849903

49. Smith K, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovascular Research. 2003;59(3):538–48. DOI: 10.1016/S0008-6363(03)00468-1

50. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. Journal of Clinical Investigation. 2005;115(8):2108–18. DOI: 10.1172/JCI24682

51. Hamid T, Prabhu SD. Erythropoietin and ventricular remodelling: a VEGF-dependent neovascularity. Cardiovascular Research. 2010;87(1):6–7. DOI: 10.1093/cvr/cvq127

52. Westenbrink BD, Ruifrok W-PT, Voors AA, Tilton RG, van Veldhuisen DJ, Schoemaker RG et al. Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure. Cardiovascular Research. 2010;87(1):30–9. DOI: 10.1093/cvr/cvq041

53. Petróczi A, Naughton DP, Pearce G, Bailey R, Bloodworth A, McNamee M. Nutritional supplement use by elite young UK athletes: fallacies of advice regarding efficacy. Journal of the International Society of Sports Nutrition. 2008;5(1):22. DOI: 10.1186/1550-2783-5-22

54. Martínez-Sanz J, Sospedra I, Ortiz C, Baladía E, Gil-Izquierdo A, Ortiz-Moncada R. Intended or Unintended Doping? A Review of the Presence of Doping Substances in Dietary Supplements Used in Sports. Nutrients. 2017;9(10):E1093. DOI: 10.3390/nu9101093

55. Blank C, Schobersberger W, Leichtfried V, Duschek S. Health Psychological Constructs as Predictors of Doping Susceptibility in Adolescent Athletes. Asian Journal of Sports Medicine. 2016;7(4):e35024. DOI: 10.5812/asjsm.35024

56. Sanchis-Gomar F, Pareja-Galeano H, Cervellin G, Lippi G, Earnest CP. Energy Drink Overconsumption in Adolescents: Implications for Arrhythmias and Other Cardiovascular Events. Canadian Journal of Cardiology. 2015;31(5):572–5. DOI: 10.1016/j.cjca.2014.12.019

57. Casella M, Dello Russo A, Izzo G, Pieroni M, Andreini D, Russo E et al. Ventricular arrhythmias induced by long-term use of ephedrine in two competitive athletes. Heart and Vessels. 2015;30(2):280–3. DOI: 10.1007/s00380-013-0455-6

58. George A. Comparison of sevoflurane and propofol. Anaesthesia. 2000;55(2):189–90. DOI: 10.1046/j.1365-2044.2000.055002190.x

59. O’Leary ME. Inhibition of Human Ether-A-Go-Go Potassium Channels by Cocaine. Molecular Pharmacology. 2001;59(2):269–77. DOI: 10.1124/mol.59.2.269

60. Billman GE. Cocaine: A Review of Its Toxic Actions on Cardiac Function. Critical Reviews in Toxicology. 1995;25(2):113–32. DOI: 10.3109/10408449509021610

61. Fisher AA, Davis MW, McGill DA. Acute Myocardial Infarction Associated with Albuterol. Annals of Pharmacotherapy. 2004;38(12):2045–9. DOI: 10.1345/aph.1E150

62. Carlsen KH. Bronchial hyperreactivity in athletes. Nordisk Medicin. 1994;109(1):16–8. PMID: 8028991

63. Visram S, Cheetham M, Riby DM, Crossley SJ, Lake AA. Consumption of energy drinks by children and young people: a rapid review examining evidence of physical effects and consumer attitudes. BMJ Open. 2016;6(10):e010380. DOI: 10.1136/bmjopen-2015-010380

64. Wilk M, Filip A, Krzysztofik M, Maszczyk A, Zajac A. The Acute Effect of Various Doses of Caffeine on Power Output and Velocity during the Bench Press Exercise among Athletes Habitually Using Caffeine. Nutrients. 2019;11(7):E1465. DOI: 10.3390/nu11071465

65. Bertoia ML, Triche EW, Michaud DS, Baylin A, Hogan JW, Neuhouser ML et al. Long-term alcohol and caffeine intake and risk of sudden cardiac death in women. The American Journal of Clinical Nutrition. 2013;97(6):1356–63. DOI: 10.3945/ajcn.112.044248

66. Larsson SC, Drca N, Jensen-Urstad M, Wolk A. Coffee consumption is not associated with increased risk of atrial fibrillation: results from two prospective cohorts and a meta-analysis. BMC Medicine. 2015;13(1):207. DOI: 10.1186/s12916-015-0447-8

67. Fletcher EA, Lacey CS, Aaron M, Kolasa M, Occiano A, Shah SA. Randomized Controlled Trial of High‐Volume Energy Drink Versus Caffeine Consumption on ECG and Hemodynamic Parameters. Journal of the American Heart Association. 2017;6(5):e004448. DOI: 10.1161/JAHA.116.004448

68. Arnar DO, Xing D, Martins JB. Alpha-2 adrenergic antagonism enhances risk of ventricular tachycardia during acute ischemia. Scandinavian Cardiovascular Journal. 2007;41(6):378–85. DOI: 10.1080/14017430701487713

69. Higgins J, Yarlagadda S, Yang B. Cardiovascular Complications of Energy Drinks. Beverages. 2015;1(2):104–26. DOI: 10.3390/beverages1020104

70. Voskoboinik A, Kalman JM, Kistler PM. Caffeine and Arrhythmias: Time to Grind the Data. JACC. Clinical electrophysiology. 2018;4(4):425–32. DOI: 10.1016/j.jacep.2018.01.012

71. Gray B, Ingles J, Medi C, Driscoll T, Semsarian C. Cardiovascular Effects of Energy Drinks in Familial Long QT Syndrome: A Randomized Cross-Over Study. International Journal of Cardiology. 2017;231:150–4. DOI: 10.1016/j.ijcard.2016.12.019

72. Frost L, Vestergaard P. Caffeine and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. The American Journal of Clinical Nutrition. 2005;81(3):578–82. DOI: 10.1093/ajcn/81.3.578

73. Балыкова Л.А., Ивянский С.А., Солдатов Ю.О., Широкова А.А., Щекина Н.В., Урзяева А.Н. L-карнитин как средство повышения адаптации и коррекции дисфункций организма подростков в ходе интенсивных физических нагрузок. Практическая медицина. 2014;9(85):140-6